Is hyperaldosteronism a pathognomonic feature of conn’s syndrome?

A 10-year-old female child presented with resistant hypertension and hypokalaemia. There was no muscle weakness or periodic paralysis. The ratio of plasma aldosterone concentration to plasma renin activity was increased. MRI of the abdomen showed the right adrenal mass. The child underwent open right adrenalectomy. she had natriuresis in the postoperative period. She was normotensive without antihypertensive drugs at discharge and 2 months after surgery.     

Vitamin D improves hepatic alterations in ACE1 and ACE2 expression in experimentally induced metabolic syndrome

Metabolic Syndrome (MetS) is a term used to describe a cluster of pathophysiological, biochemical, and metabolic criteria; including high Blood Pressure (BP), high cholesterol, dyslipidaemia, central obesity and Insulin Resistance (IR). The Renin Angiotensin System (RAS) has a regulatory function in BP, hydroelectrolyte balance, and cardiovascular function. RAS is composed of angiotensinogen (AGT), (Ang I), (Ang II), (ACE1), (ACE2), (AT1R), (AT2R), and (Ang 1–7). Vitamin D had been proved to act as a protective factor against MetS. Therefore, the study is pursued to explore vitamin D supplementation roles on hepatic RAS in MetS experimental model. At first, 36 males Albino rats were separated into 4 groups and induced to MetS under controlled circumstances for 3 months. Then, data were collected from blood samples, whereas RNA extracted from liver were analyzed using biochemical and statistical analysis tests. As a result, the major finding was proving that vitamin D can balance the expression of ACE1 and ACE2. Also, confirming that it can improve MetS components by elevating HDL and insulin levels while reducing the levels of BP, cholesterol, LDL, TG, GLU, ALT, AST, and IR. These outcomes may give a new insight into the RAS pathways associated with MetS.     

天麻钩藤饮加减对妊娠期高血压疾病患者RSS系统的影响

目的观察天麻钩藤饮加减对妊娠期高血压疾病(HDCP)患者RSS系统的影响。方法将160例HDCP患者随机分为治疗组和对照组各80例。对照组给予硫酸镁注射液静脉滴注;治疗组在硫酸镁注射液治疗基础上加用天麻钩藤饮加减治疗。于两组治疗前和治疗72 h后比较血压、24 h尿蛋白定量及血清肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)水平变化。结果两组治疗后收缩压和舒张压与治疗前比较均明显下降,差异均有统计学意义(P0.01)。治疗后,治疗组收缩压和舒张压显著优于对照组,与对照组比较差异具有统计学意义(P0.01)。两组治疗后24 h尿蛋白定量与治疗前比较均明显下降,差异均有统计学意义(P0.01)。治疗后,治疗组24 h尿蛋白定量显著优于对照组(P0.01)。治疗后,治疗组血清肾素活性(PRA)和血管紧张素Ⅱ(AngⅡ)下降明显(P0.01)。结论在硫酸镁解痉药物治疗基础上应用天麻钩藤饮加减治疗HDCP能够显著改善患者血压和24 h尿蛋白定量,其作用可能与降低血清PRA和AngⅡ水平有关。     

Structure-Based Design of Substituted Piperidines as a New Class of Highly Efficacious Oral Direct Renin Inhibitors

相似文献   

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren

ABSTRACT

Background: Aliskiren, an antihypertensive drug approved in the United States and Europe, is the first in a new class known as direct renin inhibitors. Aliskiren has been evaluated for safety and tolerability in more than 6400 patients. It has demonstrated a favorable safety and tolerability profile alone or in combination with other drugs.

Objective: This article reviews the currently available safety and tolerability data for aliskiren.

Methodology: Using the search term aliskiren, MEDLINE (no timeframe set) and major cardiovascular congresses (2005–2008) were searched. Articles and abstracts with safety and drug interaction data were included.

Findings: Aliskiren may share common adverse effects observed with angiotensin-converting enzyme (ACE)-inhibitor and angiotensin receptor blocker (ARB) therapy. In placebo-controlled trials, those commonly reported for aliskiren at the approved dosage were headache, diarrhea, and fatigue, with incidences similar to those of placebo. Aliskiren has been well tolerated in black, geriatric, diabetic, or obese patients and patients with renal or hepatic impairment. Aliskiren neither inhibits nor induces the cytochrome P450 system; it does not inhibit P-glycoprotein, but is a substrate for this drug transporter. Adding a direct renin inhibitor to another renin–angiotensin–aldosterone system (RAAS) inhibitor may further improve cardiovascular outcomes, renal outcomes, or both, without increasing the incidence of adverse effects.

Conclusions: Aliskiren is well tolerated, has an adverse effect profile comparable to that of placebo, and has a low potential for drug interactions. Data from ongoing trials evaluating the effects of aliskiren on surrogate markers, morbidity, and mortality will further define the role of direct renin inhibition in the antihypertensive armamentarium.     

Angiotensin receptor blockers: RAAS blockade and renoprotection

ABSTRACT

Introduction: Chronic kidney disease (CKD) is an increasingly prevalent public health concern and is associated with a high risk of adverse cardiovascular outcomes. Renal impairment is frequently associated with hypertension and there is compelling evidence of the benefits of antihypertensive therapy for reducing progression of kidney disease. The central role of the renin-angiotensin-aldosterone system (RAAS) in hypertension and renal disease has led to interest in the ability of RAAS-blocking agents to provide benefits beyond blood pressure control.

Scope: This review explores the mechanisms involved in CKD development, assesses markers of CKD progression, explores the role of the RAAS in renal disease, and examines RAAS blockade as a therapeutic option for renoprotection. For this purpose, a non-systematic literature review was conducted using the Medline database.

Findings: Studies in patients with diabetic renal disease have shown that RAAS blockade with angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs) reduces progression of renal disease. Similarly, several studies have demonstrated the benefits of ACE inhibitors in non-diabetic renal disease, although few studies have been conducted with ARBs in this setting. At present, there is little evidence to determine the relative merits of ARBs and ACE inhibitors in terms of clinical outcomes, although ARBs appear to have advantages in terms of renal haemodynamics and measures of renal function.

Conclusions: The beneficial effects of ARBs, which result from a combination of antihypertensive, haemodynamic, antiproteinuric and pleiotropic mechanisms, provide a strong rationale for considering the use of these agents in the treatment of high-risk patients.     

肾素瘤1例报告

目的提高肾素瘤的诊断和治疗水平。方法回顾分析收治1例肾素瘤患者的临床资料,结合文献复习进行讨论。结果患者表现有高血压、高肾素、高醛固酮血症和低血钾,行保留肾单位的肾肿瘤切除术,术后病理示:肾素瘤。患者术后血压、血浆肾素、醛固酮和血钾等恢复正常,随访1年未见肿瘤复发及高血压再发。结论肾素瘤为罕见的良性肾脏肿瘤,肿瘤根治性切除效果满意,预后良好。     

镉接触工人心血管功能研究

[目的 ]探讨镉接触对工人血压、心电图的影响及可能的作用机制 ,以保护作业工人的健康。 [方法 ]以某冶炼厂镉接触工人 86名为接触组 ,以邻近地区无镉接触史的健康工人 10 6名为对照组 ,对其血压、心电图及相关生化指标进行测定。数据经方差分析、趋势卡方检验和logistic多元回归分析 ,并计算基准剂量 (Benchmarkdose ,BMD)。 [结果 ]镉接触组工人收缩压、舒张压、高血压患病率显著高于对照组 (P <0 0 5 ) ,高血压患病率随尿镉水平增加而升高 ,有明显的剂量 反应关系 ,并得出基准剂量 2 98μg/gCr。血浆血管紧张素II、尿钠 /钾比值也随尿镉水平增高而增高。镉对高血压患病率的影响与肾功能损害与否没有显著联系。Logistic多元回归分析发现体质指数、吸烟、镉接触年限、尿镉 ,是影响高血压患病率的主要因素。接触组工人心室电压无明显改变 ,心率低于对照组 ,QRS间期和QT间期延长 ,T波及ST段改变、心动过缓等异常发生率也显著高于对照组。 [结论 ]长期接触镉可对作业工人心血管功能产生影响 ,导致血压升高 ,这可能与镉影响肾素 血管紧张素 醛固酮系统和 /或体内钾钠平衡有关。且镉可引起心电图的改变 ,可能主要是影响心室内传导。     

Low Mediterranean Diet scores are associated with reduced kidney function and health related quality of life but not other markers of cardiovascular risk in adults with diabetes and chronic kidney disease

Background and aimsHow Mediterranean-style diets impact cardiovascular and health outcomes in patients with diabetes and chronic kidney disease (CKD) is not well known. Our aim was to investigate the association between diet quality, using Mediterranean Diet Scores (MDS) and health outcomes.Methods and resultsThis is a post-hoc analysis of an RCT and longitudinal study investigating patients with diabetes and CKD. MDS was calculated annually. Scores were analyzed for correlation with lipids, HbA_1c, serum potassium, health-related quality of life (HRQOL) and depression. 178 diet records from 50 patients who attended two or more visits were included. Mean MDS was moderate (4.1 ± 1.6) and stable over time. Stage 1–2 vs 3–5 CKD had lower raw MDS (3.8 ± 1.5 vs 4.6 ± 1.5, p < 0.001). Having hyperkalemia was associated with a lower raw MDS scores (3.6 ± 1.6 vs 4.2 ± 1.5, p = 0.03) but not energy adjusted MDS. MDS was not associated with HbA_1c or lipids. High vs low MDS was associated with improved HRQOL (mental health 84.4 ± 14.3 vs 80.3 ± 17.1, p < 0.05; general health 62.6 ± 21.0 vs 56.3 ± 19.8, p < 0.001) and fewer depressive symptoms (9.1 ± 7.4 vs 11.7 ± 10.6, p = 0.01).ConclusionsLow MDS was associated with reduced kidney function and health related quality of life, but not other markers of cardiovascular risk. Further studies are needed to understand the nature and direction of the association between diet quality and disease outcomes in this population.     

Effects of WY 47987 (atrial natriuretic factor 102-126) in patients with renal insufficiency: a placebo-controlled, randomised study

We studied renal, hormonal and cardiovascular effects of ANF 102-126 (WY 47987) in seven patients with chronic renal failure (serum creatinine 25-68 mg/l) and in four normal volunteers. ANF or placebo bolus injections were given at 1, 2, and 3 micrograms/kg i.v. (each dose on separate days). As compared to placebo, ANF did not induce changes of renal excretory parameters, of plasma renin and aldosterone or of blood pressure and heart rate in patients. In healthy volunteers, however, the same dose of ANF increased urinary excretion of sodium, potassium, calcium, chloride and phosphorus as well as water, and creatinine clearances, and decreased plasma aldosterone. The data suggest blunted effectiveness of ANF bolus injections in patients with renal insufficiency.